BACKGROUND: The importance of interactions between the host and gut microbiota in the pathogenesis of irritable bowel syndrome (IBS) is becoming increasingly apparent. Probiotics offer a potential new treatment for IBS, but current results are conflicting, largely as a result of poorly designed trials and nonstandardisation of outcome measures. AIM: To assess the efficacy of a liquid, multi-strain probiotic (Symprove) in IBS. METHODS: A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS. Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/kg/day). The primary efficacy measure was the difference in change in the IBS symptom severity score (IBS-SSS) between probiotic vs. placebo at week 12. Secondary outcome measures included change in the IBS quality of life (IBS-QOL) score and change in the IBS-SSS symptom component scores. RESULTS: A total of 186 patients were randomised and 152 patients completed the study. The mean change in IBS-SSS was -63.3 probiotic vs. -28.3 placebo. The mean difference in the IBS-SSS was statistically significant [-35.0 (95% CI; -62.03, -7.87); P = 0.01]. There was no significant improvement in the IBS-QOL. No serious adverse events were reported. CONCLUSIONS: The multi-strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients with IBS, and was well tolerated. These results suggest this probiotic confers benefit in IBS and deserves further investigation (ISRCTN identifier: 77512412).
RCT Entities:
BACKGROUND: The importance of interactions between the host and gut microbiota in the pathogenesis of irritable bowel syndrome (IBS) is becoming increasingly apparent. Probiotics offer a potential new treatment for IBS, but current results are conflicting, largely as a result of poorly designed trials and nonstandardisation of outcome measures. AIM: To assess the efficacy of a liquid, multi-strain probiotic (Symprove) in IBS. METHODS: A single-centre, randomised, double-blind, placebo-controlled trial of adult patients with symptomatic IBS. Patients received 12 weeks of treatment with the probiotic or placebo (1 mL/kg/day). The primary efficacy measure was the difference in change in the IBS symptom severity score (IBS-SSS) between probiotic vs. placebo at week 12. Secondary outcome measures included change in the IBS quality of life (IBS-QOL) score and change in the IBS-SSS symptom component scores. RESULTS: A total of 186 patients were randomised and 152 patients completed the study. The mean change in IBS-SSS was -63.3 probiotic vs. -28.3 placebo. The mean difference in the IBS-SSS was statistically significant [-35.0 (95% CI; -62.03, -7.87); P = 0.01]. There was no significant improvement in the IBS-QOL. No serious adverse events were reported. CONCLUSIONS: The multi-strain probiotic was associated with a statistically significant improvement in overall symptom severity in patients with IBS, and was well tolerated. These results suggest this probiotic confers benefit in IBS and deserves further investigation (ISRCTN identifier: 77512412).
Authors: Charlotte L Kvasnovsky; Ingvar Bjarnason; Ana Nora Donaldson; Roy A Sherwood; Savvas Papagrigoriadis Journal: Inflammopharmacology Date: 2017-05-20 Impact factor: 4.473
Authors: Thomas C A Hitch; Lindsay J Hall; Sarah Kate Walsh; Gabriel E Leventhal; Emma Slack; Tomas de Wouters; Jens Walter; Thomas Clavel Journal: Mucosal Immunol Date: 2022-09-30 Impact factor: 8.701
Authors: Sarah L Alderson; Alexandra Wright-Hughes; Alexander C Ford; Amanda Farrin; Suzanne Hartley; Catherine Fernandez; Christopher Taylor; Pei Loo Ow; Emma Teasdale; Daniel Howdon; Elspeth Guthrie; Robbie Foy; Matthew J Ridd; Felicity L Bishop; Delia Muir; Matthew Chaddock; Amy Herbert; Deborah Cooper; Ruth Gibbins; Sonia Newman; Heather Cook; Roberta Longo; Hazel Everitt Journal: Trials Date: 2022-07-08 Impact factor: 2.728
Authors: Rachel D Moloney; Anthony C Johnson; Siobhain M O'Mahony; Timothy G Dinan; Beverley Greenwood-Van Meerveld; John F Cryan Journal: CNS Neurosci Ther Date: 2015-12-10 Impact factor: 5.243